ANMAT opens a permanent call for papers on AI in biomedicine: a regulatory gesture, not a breakthrough

By Zendoric · September 26, 2026.

The National Administration of Drugs, Food and Medical Technology (ANMAT), the Argentine body that regulates drugs and medical devices, has opened two permanent calls for papers in its Scientific Journal to receive articles on Artificial Intelligence in Biomedical Sciences and on Nanotechnology, according to the statement published on Argentina.gob.ar. It accepts original experimental or observational articles, systematic reviews and literature reviews, with a cap of 5,500 words and submission in Spanish. There is no closing date: the call remains open all year.

Here it is worth being precise about what this is and what it is not. It is not a scientific finding, a product or a regulatory decision on medical AI: it is a call for the scientific community to submit papers that will then undergo editorial review before publication, if they are published at all. The statement itself mentions no specific study, no prior participation figures and no technical evaluation criteria, so any reading of its real impact would have to wait to see what is submitted and what is accepted.

That said, the gesture itself deserves a brief note. That a health regulator —not a generic science ministry— opens its own channel for AI applied to biomedicine indicates that it is beginning to treat the technology as a subject of local evidence, not merely as something imported already regulated from the US FDA or Europe's EMA. It is a pattern repeating in several countries: before writing rules on AI in health, agencies seek to generate, or at least to solicit, the body of research that will underpin those rules.

It fits the underlying thesis we hold at Zendoric: AI applied to biomedicine is one of the most credible paths toward less disease and more years of healthy life in the long run. But that path is built with accumulated evidence, peer review and serious regulation, not with announcements. This call is, at most, an administrative brick in that building; the piece that will really matter is the one that tells us which research ends up being published there.